BNP PARIBAS ASSET MANAGEMENT Holding S.A. Buys 186,750 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 25.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 931,048 shares of the company’s stock after acquiring an additional 186,750 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 1.02% of Arcus Biosciences worth $14,236,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Louisiana State Employees Retirement System raised its position in shares of Arcus Biosciences by 2.6% during the 2nd quarter. Louisiana State Employees Retirement System now owns 27,500 shares of the company’s stock valued at $419,000 after purchasing an additional 700 shares during the period. ProShare Advisors LLC raised its holdings in Arcus Biosciences by 7.4% during the first quarter. ProShare Advisors LLC now owns 10,846 shares of the company’s stock valued at $205,000 after acquiring an additional 746 shares during the period. Diversified Trust Co lifted its position in shares of Arcus Biosciences by 12.1% in the second quarter. Diversified Trust Co now owns 13,545 shares of the company’s stock valued at $206,000 after acquiring an additional 1,467 shares in the last quarter. WINTON GROUP Ltd boosted its stake in shares of Arcus Biosciences by 3.3% in the second quarter. WINTON GROUP Ltd now owns 59,137 shares of the company’s stock worth $901,000 after acquiring an additional 1,872 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Arcus Biosciences by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 34,764 shares of the company’s stock worth $657,000 after acquiring an additional 1,906 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Stock Up 2.9 %

Shares of NYSE RCUS opened at $14.70 on Friday. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -4.67 and a beta of 0.89. Arcus Biosciences, Inc. has a 12-month low of $13.49 and a 12-month high of $20.31. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm’s 50-day moving average price is $16.36 and its 200-day moving average price is $16.06.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.06. The business had revenue of $48.00 million during the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company’s revenue for the quarter was up 50.0% on a year-over-year basis. During the same period last year, the company earned ($0.94) EPS. On average, equities research analysts anticipate that Arcus Biosciences, Inc. will post -3.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on RCUS. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcus Biosciences in a report on Thursday, October 3rd. HC Wainwright reissued a “neutral” rating and issued a $20.00 target price on shares of Arcus Biosciences in a report on Wednesday, November 6th. Wells Fargo & Company initiated coverage on shares of Arcus Biosciences in a research note on Tuesday, October 8th. They set an “overweight” rating and a $29.00 target price for the company. Barclays boosted their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. Finally, Evercore ISI upgraded Arcus Biosciences to a “strong-buy” rating in a research report on Friday, August 9th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $34.00.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.